Novel MS solutions inspired by MIST

Bioanalysis

Volumn 2, Issue 7, 2010, Pages 1291-1313

  Ramanathan, Ragu ^a   Josephs, Jonathan L ^a   Jemal, Mohammed ^a   Arnold, Mark ^a   Humphreys, W Griffith ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; DESLORATADINE; DRUG METABOLITE; TOLBUTAMIDE; VICRIVIROC; DRUG;

ACCURACY; CONCENTRATION RESPONSE; DRUG DETERMINATION; DRUG MONITORING; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; IN VITRO STUDY; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PROCESS DEVELOPMENT; REVIEW; RISK ASSESSMENT; VALIDATION PROCESS; ANIMAL; ENVIRONMENTAL EXPOSURE; METABOLISM; METHODOLOGY; REPRODUCIBILITY;

ANIMALS; CHROMATOGRAPHY, LIQUID; ENVIRONMENTAL EXPOSURE; HUMANS; MASS SPECTROMETRY; PHARMACEUTICAL PREPARATIONS; REPRODUCIBILITY OF RESULTS;

EID: 79951766171     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.10.83     Document Type: Review

References (57)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715 (2004). (Pubitemid 39173511)
2. GBI Research. Biomarkers in drug discovery- optimizing drug discovery timeline and costs. GBI Research, CT, USA, 76 (2010).
3. Lin J, Sahakian DC, de Morais SM, Xu JJ, Polzer RJ, Winter SM. The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr. Top. Med. Chem. 3, 1125-1154 (2003).
4. Bussiere JL. Species selection considerations for preclinical toxicology studies for biotherapeutics. Expert Opin. Drug Metab. Toxicol. 4, 871-877 (2008).
5. Gomase VS, Tagore S. Species scaling and extrapolation. Curr. Drug Metab. 9, 193-198 (2008). (Pubitemid 351843585)
6. Cheng KC, Li C, Uss AS. Prediction of oral drug absorption in humans-from cultured cell lines and experimental animals. Expert Opin. Drug Metab. Toxicol. 4, 581-590 (2008). (Pubitemid 351890740)
7. Ross D, Zhou H. Relationships between metabolic and non-metabolic susceptibility factors in benzene toxicity. Chem.Biol.Interact. 184, 222-228 (2010).
8. Saghir SA, Zhang F, Rick DL, Kan L, Bus JS, Bartels MJ. In vitro metabolism and covalent binding of ethylbenzene to microsomal protein as a possible mechanism of ethylbenzene-induced mouse lung tumorigenesis. Regul. Toxicol. Pharmacol. (2010).
9. Saha S, New LS, Ho HK, Chui WK, Chan ECY. Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity. Toxicol. Lett. 192, 141-149 (2010).
10. Malinowski HJ. The role of in vitro-in vivo correlations (IVIVC) to regulatory agencies. Adv. Exp. Med. Biol. 423, 261-268 (1997). (Pubitemid 27347211)
11. O'Hara T, Hayes S, Davis J, Devane J, Smart T, Dunne A. In vivo-in vitro correlation (IVIVC) modeling incorporating a convolution step. J. Pharmacokinet. Pharmacodyn. 28, 277-298 (2001). (Pubitemid 32643368)
12. Anderson S, Luffer-Atlas D, Knadler MP. Predicting circulating human metabolites: how good are we? Chem. Res. Toxicol. 22, 243-256 (2009).
13. Dalvie D, Obach RS, Kang P et al. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem. Res. Toxicol. 22, 357-368 (2009).
14. Hopfgartner G, Zell M, Q Trap MS. A new tool for metabolite identification. In: Using Mass Spectrometry for Drug Metabolism Studies. CRC Press, Taylor & Francis Group, USA, 277-304 (2005).
15. Hopfgartner G, Husser C, Zell M. Rapid screening and characterization of drug metabolites using a new quadrupole-linear ion trap mass spectrometer. J. Mass Spectrom. 38, 138-150 (2003). (Pubitemid 36305708)
16. Ramanathan R, Chowdhury SK, Alton KB. Oxidative metabolites of drugs and xenobiotics: LC-MS methods to identify and characterize in biological matrices. In:Identification and Quantification of Drugs, Metabolites and Metabolizing Enzymes by LC-MS . Chowdhury, SK (Ed).Elsevier, Amsterdam, The Netherlands, 225-276 (2005).
17. Ramanathan D, LeLacheur RM. Evolving role of mass spectrometry in drug discovery and development. In:Mass Spectrometry in Drug Metabolism and Pharmacokinetics , Ramanathan R (Ed).John Wiley & Sons, Inc., Hoboken, NJ, USA, 1-85 (2008).
18. Tiller PR, Yu S, Castro-Perez J, Fillgrove KL, Baillie TA. High-throughput, accurate mass liquid chromatography/tandem mass spectrometry on a quadrupole time-of-flight system as a 'first-line' approach for metabolite identification studies. Rapid Commun. Mass Spectrom. 22, 1053-1061 (2008). (Pubitemid 351468262)
19. Tiller PR, Yu S, Bateman KP et al. Fractional mass filtering as a means to assess circulating metabolites in early human clinical studies. Rapid Commun. Mass Spectrom. 22, 3510-3516 (2008).
20. Ruan Q, Peterman S, Szewc MA et al. An integrated method for metabolite detection and identification using a linear ion trap/ orbitrap mass spectrometer and multiple data processing techniques: application to indinavir metabolite detection. J. Mass Spectrom. 43, 251-261 (2008). (Pubitemid 351303446)
21. Holčapek M, Kolářová L, Nobilis M. High-performance liquid chromatography- tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites. Anal. Bioanal. Chem. 391, 59-78 (2008).
22. Ramanathan R, Zhong R, Blumenkrantz N, Chowdhury SK, Alton KB. Response normalized liquid chromatography nanospray ionization mass spectrometry. J. Am. Soc. Mass Spectrom. 18, 1891-1899 (2007). (Pubitemid 47419352)
23. Josephs JL, Grubb MF, Yang Y, Humphreys WG. A rapid approach to quantitative in vivo metabolite profiling without the need for authentic standards or labeled compounds. Presented at: 56th ASMS Conference on Mass Spectrometry and Allied Topics, Denver, CO, USA, June 1-5, (2008)
24. Josephs JL, Grubb MF, Shipkova P, Langish R, Sanders M. A comprehensive strategy for the characterization and optimization of metabolic profiles of compounds using a hybrid linear ion trap/ FTMS. Presented at: 53rd ASMS Conference on Mass Spectrometry and Allied Topics. San Antonio, TX, USA, June 2-6, (2005).
25. Josephs JL, Sanders M. Creation and comparison of MS/MS spectral libraries using quadrupole ion trap and triple-quadrupole mass spectrometers. Rapid Commun. Mass Spectrom. 18, 743-759 (2004). (Pubitemid 38451019)
26. Hop CE, Wang Z, Chen Q, Kwei G. Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J. Pharm. Sci. 87, 901-3 (1998). (Pubitemid 28319423)
27. Hamilton RA, Garnett WR, Kline BJ. Determination of mean valproic acid serum level by assay of a single pooled sample. Clin. Pharmacol. Ther. 29, 408-413 (1981). (Pubitemid 11134120)
28. Jemal M, Xia YQ. The need for adequate chromatographic separation in the quantitative determination of drugs in biological samples by high performance liquid chromatography with tandem mass spectrometry. Rapid Commun. Mass Spectrom. 13, 97-106 (1999). (Pubitemid 29064513)
29. Ramanathan R, Su AD, Alvarez N et al. Liquid chromatography/mass spectrometry methods for distinguishing N-oxides from hydroxylated compounds. Anal. Chem. 72, 1352-9 (2000). (Pubitemid 30163798)
30. Chang MS, Ji Q, Zhang J, El-Shourbagy TA. Historical review of sample preparation for chromatographic bioanalysis: pros and cons. Drug Dev. Res. 68, 107-133 (2007). (Pubitemid 47502822)
31. Zhu M, Ma L, Zhang D et al. Detection and characterization of metabolites in biological matrices using mass defect filtering of liquid chromatography/high resolution mass spectrometry data. Drug Metab. Dispos. 34, 1722-33 (2006). (Pubitemid 44427475)
32. Zhu M, Ma L, Zhang H, Humphreys WG. Detection and structural characterization of glutathione-trapped reactive metabolites using liquid chromatography-high-resolution mass spectrometry and mass defect filtering. Anal. Chem. 79, 8333-41 (2007). (Pubitemid 350060035)
33. Zhang H, Zhu M, Ray KL, Ma L, Zhang D. Mass defect profiles of biological matrices and the general applicability of mass defect filtering for metabolite detection. Rapid Commun. Mass Spectrom. 22, 2082-8 (2008). (Pubitemid 351956694)
34. Zhu P, Ding W, Tong W, Ghosal A, Alton K, Chowdhury S. A retention-time-shift-tolerant background subtraction and noise reduction algorithm (BgS-NoRA) for extraction of drug metabolites in liquid chromatography/ mass spectrometry data from biological matrices. Rapid Commun. Mass Spectrom. 23, 1563-72 (2009).
35. Zhang H, Ma L, He K, Zhu M. An algorithm for thorough background subtraction from high-resolution LC-MS data: application to the detection of troglitazone metabolites in rat plasma, bile, and urine. J. Mass Spectrom. 43, 1191-200 (2008).
36. Wright P, Miao Z, Shilliday B. Metabolite quantitation: detector technology and MIST implications. Bioanalyis 1(4), 831-845 (2009).
37. Vishwanathan K, Babalola K, Wang J et al. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards. Chem. Res. Toxicol. 22, 311-322 (2009).
38. Vishwanathan K, Babalola K, Wang J et al. Plasma pooling to obtain AUCs of metabolites present in preclinical species: addressing MIST guidance using non-radiolabeled compounds. Presented at: ISSX Meeting. San Diego, CA, USA, October 12-16 (2008).
39. Cisar P, Nobilis M, Vybiralova Z et al. Disposition study of a new potential antineoplastic agent dimefluron in rats using high-performance liquid chromatography with ultraviolet and mass spectrometric detection. J. Pharm. Biomed. Anal. 37, 1059-1071 (2005). (Pubitemid 40626728)
40. Zhu M, Zhao W, Jimenez H et al. Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab. Dispos. 33, 500-507 (2005). (Pubitemid 40393192)
41. Cai H, Josephs JL, Ramanathan R, Crafts C, Bailey BA, Humphreys WG. A novel detection technology: charged aerosol detection coupled with HPLC, UV and LTQ-orbitrap MS for drug metabolism studies. Presented at: 58th ASMS Conference on Mass Spectrometry and Allied Topics, Salt Lake City, UT, USA, May 23-27, (2010)
42. Zhang B, Li X, Yan B. Advances in HPLC Detection - towards universal detection. Anal. Bioanal. Chem. 390, 299-301 (2008).
43. Zhang D, Raghavan N, Chando T et al. LC-MS/MS-based approach for obtaining exposue estimates of metabolites in early clinical trials using radioactive metabolites as reference standards. Drug Metab. Lett. 1, 293-298 (2007).
44. Yu C, Chen CL, Gorycki FL, Neiss TG. A rapid method for quantitatively estimating metabolites in human plasma in the absence of synthetic standards using a combination of liquid chromatography/mass spectrometry and radiometric detection. Rapid Commun. Mass Spectrom. 21, 497-502 (2007). (Pubitemid 46294297)
45. Espina R, Yu L, Wang J et al. Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: implications in metabolites in safety testing. Chem. Res. Toxicol. 22, 299-310 (2009).
46. Nugent K, Zhu Y, Kent P, Phinney B, Alvarado R. CaptiveSpray: a new ionization technique to maximizing speed, sensitivity, resolution and robustness for LC-MS protein biomarker quantitation. Presented at: 57th ASMS Conference on Mass Spectrometry and Allied Topics, Philadelphia, PA, USA ,May 31-June 4, (2009)
47. Raghavan N, Ramanathan R, Comezoglu SN, Humphreys WG. LC-captivespray ionization-mass spectrometry for detection, characterization and quantification of circulating human metabolites. Presented at: 58th ASMS Conference on Mass Spectrometry and Allied Topics, Salt Lake City, UT, USA, May 23-27, (2010)
48. Penner N, Ramanathan R, Zgoda-Pols J, Chowdhury S. Quantitative determination of hippuric and benzoic acids in urine by LC-MS/MS using surrogate standards. J. Pharm. Biomed. Anal. 52, 534-543 (2010).
49. Korfmacher W. Bioanalytical assays in a drug discovery environment. In Using Mass Spectrometry for Drug Metabolism Studies. Korfmacher W (Ed).CRC Press, Boca Raton, FL, USA, 1-34, (2005).
50. Viswanathan CT, Bansal S, Booth B et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 24, 1962-1973 (2007). (Pubitemid 47389236)
51. Shah VP. The history of bioanalytical method validation and regulation: evolution of a guidance document on bioanalytical methods validation. AAPS J. 9, E43-E47 (2007).
52. Bansal S, DeStefano A. Key elements of bioanalytical method validation for small molecules. AAPS J. 9, E109-14 (2007).
53. Baillie TA, Cayen MN, Fouda H et al. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 182, 188-196 (2002).
54. Hastings KL, El-Hage J, Jacobs A, Leighton J, Morse D, Osterberg RE. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 190, 91-2; (Author reply) 93-94 (2003).
55. Smith DA, Obach RS. Seeing through the MIST: abundance versus percentage. commentary on metabolites in safety testing. Drug Metab. Dispos. 33, 1409-1417 (2005). (Pubitemid 41323986)
56. Prueksaritanont T, Lin JH, Baillie TA. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites. Toxicol. Appl. Pharmacol. 217, 143-152 (2006). (Pubitemid 44780764)
57. Robison, TW and Jacobs, A. Metabolite in safety testing. Bioanalysis, 1(7), 1193-1200 (2009).